These findings strongly implicated that miR-486 may regulate the production of VLDL by controlling the expression of the PTEN, FoxO1a, and MTTP proteins, and suggested a potential theraputic strategy for dyslipidemia. This evidence concerns the gene MTTP and metabolic syndrome.